Shanghai-based biopharmaceutical company EpimAb Biotherapeutics has closed a $74 million Series B round co-led by China’s State Development Investment Corporation (SDIC) Fund and Sherpa Healthcare Partners, it said in a statement on Wednesday.
Other investors that joined the round include South China Venture Capital (SCVC), further private investment entities and existing investors from EpimAb’s Series A round, bringing the total funding amount raised by the company to over $100 million.
